PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

KKR to buy Japan’s Bushu Pharmaceuticals in $749m deal

Private equity giant KKR & Co Inc has revealed plans to acquire Japanese drug developer Bushu Pharmaceuticals from BPEA EQT, a Hong Kong-based private equity firm, according to a report by Reuters.

Private equity giant KKR & Co Inc has revealed plans to acquire Japanese drug developer Bushu Pharmaceuticals from BPEA EQT, a Hong Kong-based private equity firm, according to a report by Reuters.

While financial details of the deal have not been revealed, the report cites unnamed sources as revealing that a Bloomberg report published in August suggested a transaction may value Bushu Pharma at upwards of JPY100 billion ($749 million).

According to a press statement from KKR, the investment firm plans to expand Bushu Pharma into new, and growth, segments including injectables, and also invest in further capacity expansion and quality control, while seeking additional growth opportunities.
 

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Featured